Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain

Table 1 Quantification of western blots on ipsilateral vs contralateral L4 (uninjured) DRGs from SNL rats 17 days post-surgery.

RAT SNL
Uninjured L4 DRG vs. Contralateral
	Contra	Contra	Ipsi	Ipsi
Protein/Standardization	Mean %	SEM	Mean %	SEM	P-value
p-mTOR/mTOR	100	17.9	402.8	63.6	0.001
p-mTOR/beta III tubulin	100	19.0	425.7	92.0	0.012
mTOR/beta III tubulin	100	12.1	86.0	34.4	NS
p-4EBP/4EBP	100	11.6	100.1	9.3	NS
p-4EBP/beta III tubulin	100	15.8	190.3	22.2	0.003
4EBP/beta III tubulin	100	17.8	182.6	14.8	0.002
p-ERK/ERK	100	11.0	121.0	17.1	NS
p-ERK/beta III tubulin	100	19.8	111.3	13.2	NS
ERK/beta III tubulin	100	12.3	97.2	4.0	NS
p-eIF4alpha/eIF4alpha	100	13.5	60.1	8.0	0.026
p-eIF2alpha/beta III tubulin	100	19.7	61.8	7.2	NS
eIF2alpha/beta III tubulin	100	13.6	106.9	6.3	NS
mov10/beta III tubulin	100	20.8	220.9	37.0	0.008
rck/beta III tubulin	100	12.5	123.5	14.1	NS
eIF4A/beta III tubulin	100	15.3	102.5	14.7	NS
fbxw7/beta III tubulin	100	45.1	102.3	30.5	NS
p-AKT/total AKT	100	10.9	112.8	14.7	NS
p-AKT/beta III tubulin	100	6.0	107.8	12.2	NS
AKT/beta III tubulin	100	10.8	92.5	3.9	NS
p-mTOR/GAPDH	100	14.1	387.2	72.4	0.006
p-4EBP/GAPDH	100	13.3	162.6	12.0	0.002
4EBP/GAPDH	100	11.8	163.1	9.6	0.000
mov10/GAPDH	100	19.4	195.6	34.6	0.025

ISSN: 1744-8069